^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
VTP-600
i
Other names: VTP-600, ChAdOx1-MAGEA3-NYESO/MVA-MAGEA3 vaccine, ChAdOx-MVA cancer vaccine, VTP600, VTP 600
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Barinthus Bio, Cancer Research UK, Ludwig Institute for Cancer Research
Drug class:
Immunostimulant, NY ESO 1 inhibitor, MAGE-A3 modulator
Related drugs:
3years
A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 (clinicaltrials.gov)
P1/2, N=86, Recruiting, Cancer Research UK | Not yet recruiting --> Recruiting
Enrollment open • Checkpoint inhibition
|
PD-L1 (Programmed death ligand 1) • MAGEA3 (MAGE Family Member A3)
|
VTP-600
over3years
A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 (clinicaltrials.gov)
P1/2, N=86, Not yet recruiting, Cancer Research UK | Initiation date: May 2021 --> Sep 2021
Trial initiation date • Checkpoint inhibition
|
PD-L1 (Programmed death ligand 1) • MAGEA3 (MAGE Family Member A3)
|
VTP-600
over3years
A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 (clinicaltrials.gov)
P1/2, N=86, Not yet recruiting, Cancer Research UK
New P1/2 trial • Checkpoint inhibition
|
PD-L1 (Programmed death ligand 1) • MAGEA3 (MAGE Family Member A3)
|
VTP-600
Share via
